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Rhizomelic chondrodysplasia punctata (RCDP) is a genetically heterogeneous, autosomal recessive disorder of
peroxisomal metabolism that is clinically characterized by symmetrical shortening of the proximal long bones,
cataracts, periarticular calcifications, multiple joint contractures, and psychomotor retardation. Most patients with
RCDP have mutations in the PEX7 gene encoding peroxin 7, the cytosolic PTS2-receptor protein required for
targeting a subset of enzymes to peroxisomes. These enzymes are deficient in cells of patients with RCDP, because
of their mislocalization to the cytoplasm. We report the mutational spectrum in the PEX7 gene of 78 patients
(including five pairs of sibs) clinically and biochemically diagnosed with RCDP type I. We found 22 different
mutations, including 18 novel ones. Furthermore, we show by functional analysis that disease severity correlates
with PEX7 allele activity: expression of eight different alleles from patients with severe RCDP failed to restore the
targeting defect in RCDP fibroblasts, whereas two alleles found only in patients with mild disease complemented
the targeting defect upon overexpression. Surprisingly, one of the mild alleles comprises a duplication of nucleotides
45–52, which is predicted to lead to a frameshift at codon 17 and an absence of functional peroxin 7. The ability
of this allele to complement the targeting defect in RCDP cells suggests that frame restoration occurs, resulting in
full-length functional peroxin 7, which leads to amelioration of the predicted severe phenotype. This was confirmed
in vitro by expression of the eight-nucleotide duplication–containing sequence fused in different reading frames to
the coding sequence of firefly luciferase in COS cells.
Introduction
Rhizomelic chondrodysplasia punctata (RCDP) is an
autosomal recessive peroxisomal disorder with a distinct
clinical phenotype consisting of dwarfism due to sym-
metrical shortening of the proximal long bones (i.e., rhi-
zomelia), cataracts, periarticular calcifications, multiple
joint contractures, specific radiological abnormalities,
and psychomotor retardation. The rhizomelia distin-
guishes RCDP clinically from other bone dysplasias. The
disorder is genetically heterogeneous, consisting of three
groups of patients with defects in different genes. By far
the most common of these is RCDP type 1 (MIM
215100), which results from an inability to target pro-
teins that contain a peroxisomal targeting signal type 2
(PTS2) to peroxisomes, because of mutations in PEX7
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(GenBank accession numbers AF180806–AF180814),
which encodes the cytosolic PTS2-receptor protein per-
oxin 7 (Braverman et al. 1997; Motley et al. 1997; Pur-
due et al. 1997). RCDP type 2 (MIM 222765) and type
3 (MIM 600121) are clinically indistinguishable from
type 1 but are caused by mutations in the genes encoding
the first and second enzyme of ether-phospholipid bio-
synthesis, respectively. Patients with RCDP type 2 have
mutations in the gene that encodes peroxisomal dihy-
droxyacetonephosphate acyltransferase (Thai et al.
1997; Ofman et al. 1998), and patients with RCDP type
3 have mutations in the gene that encodes peroxisomal
alkyl-dihydroxyacetonephosphate synthase (Wanders et
al. 1994; de Vet et al. 1998).
Two well-defined targeting signals for directing pro-
teins to the peroxisomal matrix have been identified.
Most peroxisomal matrix proteins contain a PTS1 (per-
oxisome targeting signal type 1), which is a loosely con-
served C-terminal tripeptide (Gould et al. 1989; Mullen
et al. 1997; Sacksteder and Gould 2000; Subramani et
al. 2000). PTS2 is found in only a few peroxisomal
proteins and is a bipartite amino acid motif (located on
the N terminus), the consensus of which comprises R[L/
V/I]X5[H/Q][L/A] (Swinkels et al. 1991; Tsukamoto et
al. 1994; Sacksteder and Gould 2000; Subramani et al.
2000). Two different receptor proteins have been iden-
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Table 1
Primer Sets Used for PEX7 Mutation Analysis
Analysis Type, Amplicon Name
(Size in bp), and Primer Name Sequencea
cDNA:
Fragment 1 (373)
PEX781 to 61 5
′-[21M13]-TCTCTCTAACCGCGCCAGTG-3′
PEX7 256–236 5
′-[M13Rev]-AGGTGATGAGGACATGTTCGT-3′
Fragment 2 (494)
PEX7 148–168 5
′-[21M13]-ATATTGGATCCAGATGAAGCT-3′
PEX7 605– 586 5
′-[M13Rev]-AAGATTTCTGCCTGATGTGC-3′
Fragment 3 (697)
PEX7 341–362 5
′-[21M13]-TGTATAGTGTTGATTGGAGCCA-3′
PEX7 1001–981 5
′-[M13Rev]-ATCTTCTGTTTCTGACCAAAG-3′
gDNA:
Exon 1 (633)
PEX7 245 to 226 5
′-[21M13]-GATCACTCCCCTGATAGATC-3′
PEX7-IVS1-rev 5′-[M13Rev]-ATGCACTTGCACACAACTGG-3′
Exon 2 (406)
PEX7-IVS1-fw 5′-[21M13]-CATTTGGTATTCAAGGTCCC-3′
PEX7-IVS2-rev 5′-[M13Rev]-TATGCAAACGCCAAGGTTCC-3′
Exon 3 (357)
PEX7-IVS2-fw 5′-[21M13]-TTGTGTAGCTGCCTATGTAAg-3′
PEX7-IVS3-rev 5′-[M13Rev]-ATGCTACGTTAACTTGTCCC-3′
Exon 4  5 (704)
PEX7-IVS3-fw 5′-[21M13]-TGCAATGTTGAACTTGATGG-3′
PEX7-IVS5-rev 5′-[M13Rev]-CCATTCACTACAAGTAAGGC-3′
Exon 6 (374)
PEX7-IVS5-fw 5′-[21M13]-AGGTGGCAATATCCTAACAC-3′
PEX7-IVS6-rev 5′-[M13Rev]-TTAATGGTCCAGGAAGCACC-3′
Exon 7 (324)
PEX7-IVS6-fw 5′-[21M13]-TTTCTAGTAGGAAAGCCTGC-3′
PEX7-IVS7-rev 5′-[M13Rev]-TAACTCCAATCCCTAAACCC-3′
Exon 8 (381)
PEX7-IVS7-fw 5′-[21M13]-CTCAAATTATAGCATATATGCC-3′
PEX7-IVS8-rev 5′-[M13Rev]-TTTAAATGTACCCATCTCAG-3′
Exon 9 (416)
PEX7-IVS8-fw 5′-[21M13]-ACGTAGGGCTTAATAGTGGG-3′
PEX7-IVS9-rev 5′-[M13Rev]-GTTTAATGCTCAAACGCTCC-3′
Exon 10 (322)
PEX7-IVS9-fw 5′-[21M13]-GAATTTTGTATGTCTAAATACG-3′
PEX71138–1120 5
′-[M13Rev]-TAAAGTCTTTATCAGCTCC-3′
a 21M13 p 5′-TGTAAAACGACGGCCAGT-3′; M13Revp 5′-CAGGAAACAGC-
TATGACC-3′.
tified that recognize these two PTSs in the cytoplasm
and deliver the PTS-containing proteins to the peroxi-
somal membrane for import (for review, see Sacksteder
and Gould 2000; Subramani et al. 2000). The inability
to import PTS-containing proteins into peroxisomes
renders most of the peroxisomal enzymes unstable or
inactive in the cytoplasm of mammalian cells. The en-
zymatic deficiencies that result from an inability to im-
port PTS-containing proteins are manifested as the se-
vere disorders of peroxisome biogenesis, including
Zellweger syndrome and RCDP (Wanders et al. 1995).
The biochemical deficiencies caused by the defective
peroxin 7 in patients with RCDP type 1 reflect its func-
tion in PTS2-mediated protein transport: the PTS2-con-
taining peroxisomal 3-ketoacyl-CoA thiolase remains
unprocessed in the cytosol, and the PTS2-containing
enzymes alkyl-dihydroxyacetonephosphate synthase
and phytanoyl-CoA hydroxylase are both deficient
(Heymans et al. 1985; Hoefler et al. 1988). The finding
that patients with RCDP type 2 and type 3 have single-
enzyme deficiencies in the ether-phospholipid biosyn-
thetic pathway that result in the same clinical presen-
tation as patients with RCDP type 1, indicates that the
phenotype of RCDP is caused predominantly by a de-
ficiency of ether phospholipids.
Few patients have been identified who have a mild
form of RCDP type 1 displaying the same set of bio-
chemical abnormalities as are observed in patients with
classical type 1 but with a milder clinical presentation
in that they lack the rhizomelia and have a much longer
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life expectancy (Poll-The et al. 1991; Smeitink et al.
1992; Nuoffer et al. 1994). In the patients with mild
RCDP, ether-phospholipid biosynthesis is only moder-
ately deficient, and residual enzyme activities are inter-
mediate between those of patients with severe type 1
disease and those of normal controls (Smeitink et al.
1992; Nuoffer et al. 1994; Barth et al. 1996; Baum-
gartner et al. 1998). We have hypothesized previously
that mutations in the PEX7 gene of these patients only
partially affect the function of the PTS2 receptor (Barth
et al. 1996; Motley et al. 1996). The finding that pa-
tients with a mild clinical course of the disease have
higher residual levels of ether phospholipids confirms
the importance of ether phospholipids in the pathogen-
esis of RCDP. Until now, however, this biochemical cor-
relation with phenotype had not been linked to PEX7
genotype.
Here, we report the mutational spectrum in the PEX7
gene of 78 patients clinically diagnosed with RCDP type
1 and biochemically confirmed in our laboratory. In
addition, we functionally analyzed 10 of the 22 different
mutant alleles by assessing the ability of the encoded
proteins to target a PTS2-tagged green fluorescent pro-
tein (GFP) to peroxisomes after overexpression in PTS2-
mediated import-deficient cells. We found that the clin-
ical severity of RCDP correlates with the residual
activity of the PEX7 allele. Interestingly, two of the
patients analyzed were homozygotes for a frameshift
introducing an 8-nt duplication in the 5′ region of the
PEX7 coding sequence, yet the disease was mild in both
patients. Functional analysis of this PEX7 allele indi-
cates that the duplication sequence leads to partial res-
toration of the reading frame, resulting in amelioration
of a predicted severe phenotype.
Subjects and Methods
Patients
All patients analyzed for PEX7 mutations in the pre-
sent study showed the clinical characteristics described
for RCDP. After we obtained informed consent, samples
were collected from patients and, when indicated, from
their parents and were sent to our laboratory for the
biochemical and molecular diagnosis of RCDP. For the
majority of patients, the biochemical diagnosis of RCDP
type 1 was substantiated by detailed studies in primary
skin fibroblasts, which included the following analyses:
(1) de novo plasmalogen synthesis, (2) dihydroxyace-
tonephosphate acyltransferase and alkyl-dihydroxyace-
tonephosphate synthase activity measurements, (3) anal-
ysis of very-long-chain fatty-acid levels, (4) phytanic acid
alpha-oxidation, (5) catalase immunofluorescence, and
(6) immunoblot analysis of peroxisomal thiolase (Wan-
ders et al. 1995).
PEX7 Mutation Analysis
PEX7 mutation analysis in the patients and their par-
ents was performed at the cDNA and/or the genomic
DNA level. Total RNA and genomic DNA were isolated
from primary skin fibroblasts or lymphocytes of patients
and, when available, their parents, using the Wizard
RNA purification kit and the Wizard genomic DNA pu-
rification kit, respectively (Promega). For mutation anal-
ysis at the cDNA level, the coding region of PEX7 cDNA
was amplified by PCR in three overlapping fragments
from first-strand cDNA prepared from total RNA, as
described elsewhere (Ijlst et al. 1994). The sequences of
the cDNA primer sets are shown in table 1. The am-
plification of the PEX7 cDNA fragments was performed
with our standard PCR program, which started with 2
min of denaturation at 96C, followed by 30 cycles of
30 s at 94C, 30 s at 50C, and 1 min at 72C, followed
by a final extension step of 5 min at 72C. For mutation
analysis at the genomic level, the protein-encoding por-
tions of exons 1 and 10 and the entire exons 2–9, plus
flanking intron sequences from the PEX7 gene, were
amplified by PCR, using the primer sets shown in table
1. The genomic primer sets were designed on the basis
of the recently published PEX7 gene structure (Brav-
erman et al. 2000; GenBank). Exons 4/5, 7, 8, 9, and
10 were amplified using a PCR program that started
with a denaturation step at 96C for 2 min, followed by
4 cycles of 30 s at 96C, 30 s at 55C (50C for exon
8), and 1 min at 72C, and 24 cycles of 30 s at 94C,
30 s at 55C, and 1 min at 72C, followed by a final
extension step of 10 min at 72C. Exons 1, 2, 3, and 6
were amplified using a “touchdown” amplification pro-
gram consisting of a denaturation step of 2 min at 96C,
followed by 10 cycles of 30 s at 96C, 30 s at 65–55C,
and 1 min at 72C, during which the annealing tem-
perature was lowered 1C per cycle, followed by 24 cy-
cles of 30 s at 96C and 1 min at 72C and a final
extension step of 10 min at 72C.
Forward and reverse primers used for PEX7mutation
analysis were tagged with a 21M13 sequence and
M13rev sequence, respectively. PCR fragments were se-
quenced in two directions using “21M13” and
“M13rev” fluorescent primers on an Applied Biosystems
377A automated DNA sequencer, according to the man-
ufacturer’s protocol (PE Biosystems).
Functional Analysis of PEX7 Alleles
Selected PEX7 mutations identified in the patients
were introduced in control PEX7 cDNA cloned into
the EcoRI-XbaI sites of pUC19 (New England Bio-
Labs). The PEX7 alleles encoding the amino acid sub-
stitutions L70W (209TrG), W95G (283TrG), D134N
(400GrA) and the allele harboring the 370-396del27nt
deletion were amplified from the corresponding patient’s
Table 2
PEX7 Mutations Identified in 78 Patients with RCDP Type 1
NUCLEOTIDE
CHANGEa EXON
PREDICTED EFFECT
ON CODING
SEQUENCE
NO. OF PATIENTS
IDENTIFIED BY
ALLELE
FREQUENCYb
(n p 146)
ETHNIC/GEOGRAPHIC ORIGIN
OF INDEX PATIENTS (NO.)
cDNA
Analysis
gDNA
Analysis
/ / / /
Missense:
209TrG 3 L70W 1 1.4 Turkish (1)
257GrA 3 C86Y 1 .7 Dutch (1)
283TrG 3 W95G 3 4.1 Israelic (3)
400GrA 4 D134N 1 1.4 Italian (1)
649GrAc 7 G217R 3 2.0 British (2), Dutch (1)
653CrTc,d,e 7 A218V 6 1 1 3 12.3 Spanish (5), French (3), German (1), American (1), Chilean (1)
722ArT 7 H241L 1 .7 Spanish (1)
785CrT 8 S262L 1 .7 Dutch (1)
854ArG 9 H285R 1 .7 Dutch (1)
Nonsense:
60CrA 1 Y20X 1 .7 Turkish (1)
120CrG 1 Y40X 2 1.4 British (1), German (1)
345TrG 4 Y115X 1 .7 Swedish (1)
376CrT 4 Q126X 1 .7 Italian (1)
695CrTe 7 R232X 1 1.4 Japanese (1)
875TrA c,d,e,f 9 L292X 30g 6 8h 4 52.1 Dutch (23), German (15), British (5), Danish (1), Belgian (1), Australian (1), Chilean (1)
Deletion:
195-196delCT 3 FDW64-66VALRi 1 .7 Swedish (1)
370-396del27nt 4 Del aa124-132 3 2 6.8 Turkish (3), German (2)
842delC 9 Frameshift 1 .7 Turkish (1)
Insertion:
52ins GGGACGCC 1 Frameshift 2 2.7 Swiss (1), French (1)
Splicing:
IVS11GrC ? 1 .7 British (1)
IVS13GrC ? 1 1.4 Dutch (1)?
IVS91GrCj Frameshift 1 5 4.8 British (3), Italian (1), French (1), Dutch (1)
Unknownk 2 1.4 Dutch (2)
a Mutations described elsewhere are underlined.
b To calculate allele frequency, apparent homozygotes have been assumed to be homozygotes, and sibs have been excluded.
c Braverman et al. (1997).
d Motley et al. (1997).
e Shimozawa et al. (1999).
f Purdue et al (1997).
g Includes four sib pairs; homozygosity was confirmed in parents of three patients.
h Includes one sib pair; homozygosity was confirmed in parents of six patients..
i Deletion of 2 nt in exon 3 results in a 3′ shift of the intron 2 splice-acceptor site from position 188 to position 183, with the predicted substitution of amino acid residues FDW
at position 64–66 by VALR.
j Splice donor site mutation resulting in aberrantly spliced mRNA lacking exon 9 (804-903del100nt).
k Two patients were heterozygous for L292X at the genomic level but homozygous at the cDNA level. No second mutation was identified.
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cDNA samples, using the primers PEX7148–168 and
PEX7605–586. The PCR fragments were digested with
HindIII and BclI and ligated into the corresponding re-
striction sites of the control PEX7 cDNA in pUC19. The
PEX7 alleles encoding the amino acid substitutions
G217R (649GrA), A218V (653CrT), S262L
(785CrT), H285R (854ArG), and L292X (875TrA)
were amplified from the corresponding patient’s cDNA
samples, using the primers PEX7341–362 and PEX71001–981.
The PCR fragments were digested with BstEII and BglII
and ligated into the corresponding restriction sites of the
control PEX7 cDNA in pUC19. The 8-nt–duplication
allele was amplified from the corresponding patient
cDNA sample, using an EcoRI-tagged PEX71-19 primer
(5′-CGGGAATTCCGGATGAGTGCGGTGTGCGGT-
G-3′ [underline indicates EcoRI site]) and the PEX7256-
236 primer. After digestion with EcoRI and HindIII, this
fragment was ligated into the corresponding sites of the
control PEX7 cDNA in pUC19.
The constructed PEX7 alleles were released from
pUC19 as EcoRI-XbaI fragments and ligated into the
EcoRI-XbaI sites of the pcDNA3 vector (Invitrogen) un-
der the transcriptional control of the cytomegalovirus
(CMV) promoter. To determine the consequence of
the mutations for the function of peroxin 7, the ex-
pression plasmids were introduced by nuclear microin-
jection in primary skin fibroblasts from a patient with
RCDP homozygous for the L292X mutation and were
cultured in Dulbecco’s minimal essential medium sup-
plemented with 10% fetal bovine serum and penicillin/
streptomycin. Microinjection of PTS2-tagged GFP (final
concentration of 90 mg/ml) and the various PEX7
pcDNA3 expression plasmids (final concentration 270
mg/ml) was followed by immunofluorescence micros-
copy, using anti-GFP antiserum (Clontech) and anti-rab-
bit Cy3 conjugates to assess the import of PTS2-tagged
GFP into peroxisomes, as described elsewhere (Motley
et al. 1994, 1997).
Luciferase Reading Frame Restoration Assay
The luciferase coding region lacking its initiation co-
don was fused in three different reading frames behind
a short (8-nt) duplication containing a PEX7 cDNA se-
quence comprising 30 nucleotides and extending from
the A at position 30 to the C at position 60. The fusion
constructs were created by means of PCR, using control
firefly luciferase cDNA in vector pcDNA1 as template,
an SP6 primer as the reverse, and the following primers
as the forward primers: frame 0, 5′-CCCGGATCCATG-
CTGCGGACGCCGGGACGCCGGGACGCCGAAGA-
CGCCAAAAACATAAAGAAAG-3′; frame1, 5′-CCC-
GGATCCATGCTGCGGACGCCGGGACGCCGGGA-
CGCCAGAAGACGCCAAAAACATAAAGAAAG-3′;
and frame 2, 5′-CCCGGATCCATGCTGCGGACGC-
CGGGACGCCGGGACGCCACGAAGACGCCAAAA-
ACATAAAGAAAG-3′ (underlined sequence derived
from PEX7, boldfaced italic sequence derived from fire-
fly luciferase). The PCR products were cloned into the
BamHI-XhoI sites of pcDNA3 and verified by sequenc-
ing to exclude errors introduced by PCR. The different
constructs were transfected into COS cells by calcium
phosphate precipitation (Chen and Okayama 1987). As
a control for transfection efficiency, an expression plas-
mid encoding LacZ (Promega) was cotransfected with
the PEX7-luciferase fusion constructs. Cells were har-
vested after 48 h, and luciferase was measured using the
luciferase assay system of Promega according to the
manufacturer’s instructions. Luciferase activities were
corrected for transfection efficiency by normalization
with b-galactosidase activity (Rosenthal 1987).
In Vitro Expression of PEX7 Alleles
The various PEX7-pcDNA3 plasmids used for ex-
pression in fibroblasts (from the CMV promoter) were
also used for expression in vitro (from the T7 promoter),
using the TNTCoupled Reticulocyte Lysate System (Pro-
mega) according to the manufacturer’s instructions. The
labeled proteins were tested on 7.5% SDS polyacryl-
amide gels and were visualized by autoradiography.
Secondary Structure Predictions of Peroxin 7
The human peroxin 7 amino acid sequence was an-
alyzed by use of the PHD program for protein structure
prediction (Rost 1996). Predictions were re-evaluated
and confirmed by analysis in the ExPasy Secondary
Structure Prediction Package and by aligning the peroxin
7 sequence with the sequence of the b-subunit of het-
erotrimeric G protein, a WD-repeat–containing protein
for which the crystal structure has been resolved (Sondek
et al. 1996). The combined data allowed the construc-
tion of the topology folding model of peroxin 7.
Results
PEX7 Mutations in Patients with RCDP Type 1
Sequence analysis of the PEX7 cDNA and/or gene of
73 patients (excluding the five sib pairs) in whom RCDP
type 1 was clinically and biochemically diagnosed re-
vealed 22 different mutations, 18 of which have not been
reported before. The mutations are detailed in table 2
and involve three deletions and one insertion and nine
missense, six nonsense, and three splice-site mutations.
Of the 18 patients who appeared to be heterozygous
for two mutations, 4 were confirmed as compound het-
erozygotes by analysis of parental PEX7 DNA or by
finding the mutations on two different alleles (cDNA
subcloning). Two patients appeared to be homozygous
for the L292X mutation at the cDNA level but were
Figure 1 Alignment of peroxin 7 orthologues from four different phyla, represented by human, Drosophila melanogaster, Arabidopsis
thaliana, and Saccharomyces cerevisiae. Alignment was determined using the Clustal W program (Thompson et al. 1994). Amino acids that
are identical and conserved in at least three sequences are indicated in blackened and shaded boxes, respectively. The horizontal black lines
underneath the alignment indicate the positions of the six WD repeats. Mutations identified in the patients and affecting the human peroxin 7
sequence are indicated above the alignment as amino acid substitutions (one-letter code), nonsense mutations (*), and frameshift mutations (f).
The FDW64–66VALR mutation is indicated (-&-), and the overlined residues represent the 370-369del27nt mutation (deletion of amino acid
residues 124–132). For details of these mutations, see table 2.
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Figure 2 Functional complementation of PTS2-mediated peroxisomal protein import by PEX7 alleles. Ten different PEX7 alleles identified
in the patients were coexpressed with PTS2-tagged GFP to test their ability to restore PTS2-mediated peroxisomal protein import in skin
fibroblasts from a patient homozygous for the L292X mutation. A, Expression of control PEX7 resulted in punctate peroxisomal fluorescence
in 190% of GFP-expressing cells, with 20%–40% of the cells showing cytosolic fluorescence in addition to punctate fluorescence. B, None of
the eight alleles derived from patients with severe RCDP (see Subjects and Methods) were able to complement the PTS2-mediated protein import
defect, and PTS2-tagged GFP fluorescence was invariably cytosolic (the L70W allele, which is representative for all other seven alleles, is shown).
C and D, Expression of the 8-nt duplication PEX7 allele resulted in punctate peroxisomal fluorescence in 90% of the cells. In 40%–60% of
the GFP-expressing cells, however, cytosolic fluorescence and punctate fluorescence were evident, indicating that complementation by this allele
is less efficient than complementation by the control allele. E and F, Expression of the H285R PEX7 allele resulted in punctate peroxisomal
fluorescence in 50%–70% of GFP-expressing cells, but this was always against a background of cytosolic fluorescence; no cells were found in
which fluorescence was exclusively punctate.
heterozygotes at the genomic level; no second mutation
could be detected in the PEX7 gene. Analysis of genomic
PEX7 DNA identified 14 patients as apparent homo-
zygotes; for 6 of these, the homozygosity was confirmed
by analysis of parental PEX7 DNA. PEX7 cDNA anal-
ysis identified 41 apparent homozygotes, with homo-
zygosity confirmed by parental PEX7 DNA analysis in
4 of them.
When we assumed that all apparent homozygotes
were true homozygotes, we found the nonsensemutation
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Figure 3 In vitro transcription and translation of PEX7 alleles.
The same 10 constructs used for the complementation studies were
used to express the PEX7 alleles in a T7-coupled reticulocyte lysate
expression system. Each allele produced a polypeptide of approxi-
mately the expected size, with the exception of the 8-nt duplication
allele, which gave no detectable product.
Table 3
Reading Frame–Dependent Restoration of Luciferase Activity by the 8-nt Duplication
Frame Constructa
Luciferase Activityb
(%)
0 PCMV- GAA …
c 0
0 PCMV-ATG CTG CGG ACG CCG GGA CGC CGG GAC GCC GAA … 100
1 PCMV-ATG CTG CGG ACG CCG GGA CGC CGG GAC GCC AGA A… 1.1
2 PCMV-ATG CTG CGG ACG CCG GGA CGC CGG GAC GCC ACG AA… 4.3
a ATG codon following CMV promoter (PCMV) is second ATG of PEX7 (nt 31–33 of cDNA). Open reading
frame of firefly luciferase starts at the second codon and is shown in bold. Underlined sequence denotes the
8-nt duplication
b 100% is 3.106 units luciferase activity normalized for b-galactosidase activity
c Control construct without PEX7 sequence and without the luciferase ATG.
L292X to be by far the most common mutation causing
RCDP type 1; it had an allele frequency of ∼52% and
was detected in 43 of the 73 patients (table 2). Other
relatively common mutations are A218V (11 patients;
allele frequency ∼12%), 370-369del27nt (5 patients; al-
lele frequency ∼7 %), and IVS91GrC (6 patients; al-
lele frequency ∼5%). Remaining mutations were iden-
tified in only one to three patients.
Three of the patients we analyzed showed a mild clin-
ical presentation of the disease and no rhizomelia. Sur-
prisingly, two of these patients were apparent homo-
zygotes for an 8-nt duplication of nucleotides 45–52 in
PEX7 cDNA (52insGGGACGCC), predicted to result
in a frameshift at codon 17 and no functional peroxin
7. The homozygosity for this duplication was confirmed
by PCR amplification of genomic DNA of both patients
and is in line with the reported consanguinity of the
respective parents (Poll-The et al. 1991, Nuoffer et al.
1994). It is not known, however, whether the two pa-
tients are related. The third patient with mild RCDP is
a compound heterozygote for two mutations, L292X
and H285R. As the common L292X nonsense mutation
does not lead to functional peroxin 7, the H285R mu-
tation must be the allele responsible for the mild pre-
sentation of the disease in this patient.
The positions of all the mutations identified in the
coding region of PEX7 are shown in an alignment of
human peroxin 7 with its orthologues from three evo-
lutionarily distant phyla, represented byDrosophilamel-
anogaster (Flybase), Arabidopsis thaliana, and Saccha-
romyces cerevisiae (fig. 1). Most missense mutations
affect amino acids that are highly conserved among the
orthologues and/or predicted to be essential for the func-
tional integrity of one of the six WD repeats that are
present in peroxin 7.
Functional Analysis of PEX7 Alleles
To test the effect of mutations on the function of per-
oxin 7, we expressed 10 different patient PEX7 alleles,
under transcriptional control of the CMV promoter, in
cultured skin fibroblasts from a confirmed L292X ho-
mozygote, together with a PTS2-tagged GFP (as reporter
protein for PTS2-mediated protein import into peroxi-
somes [fig. 2]). Expression of a control PEX7 allele re-
sulted in restoration of peroxisomal PTS2-mediated pro-
tein import, as indicated by the appearance of punctate
peroxisomal fluorescence (fig. 2A). In contrast, none of
the eight different PEX7 alleles derived from patients
with severe RCDP were able to restore PTS2-mediated
protein import, and the fluorescence observed remained
invariably diffuse, indicative of a cytosolic localization
of PTS2-tagged GFP (shown only for the L70W allele,
in fig. 2B). Expression of the two alleles found in the
patients with mild RCDP, however, resulted in res-
toration of PTS2-mediated peroxisomal protein im-
port, although to varying degrees (fig. 2C–F). Import
restoration by the 8-nt–duplication allele was rather
efficient, with many GFP-expressing cells showing punc-
tate peroxisomal fluorescence without background cy-
tosolic labeling and with only few cells showing partial
import restoration (fig. 2C andD). Complementation of
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Figure 4 Predicted folding topology of peroxin 7 based on WD-repeat secondary structure features and locations of PEX7 mutations. A,
Folding of an individual WD repeat. Each WD repeat is composed of four b-strands named “a,” “b,” “c,” and “d” (arrows) separated by
loops and turns (lines), which together make up one blade of a propeller. The top region of a folded WD repeat is defined by the tight turn
between b-strands b and c. B, Topology model showing the structural arrangement of the six WD repeats predicted for peroxin 7 and mapping
of the various amino acid residues affected by the missense mutations identified in the patients with RCDP. The WD repeats (indicated as WD-
1–WD-6) are alternately shaded and blackened and are separated by connecting loops.
the import defect by the second mild allele, H285R, was
weaker and, although punctate peroxisomal fluores-
cence often could be detected, it was always against a
background of cytosolic labeling (fig. 2E and F). These
results indicate that the severity of the clinical phenotype
correlates with the ability of a PEX7 allele to restore
PTS2-mediated protein import into peroxisomes in
RCDP cells.
In Vitro Expression of Patient PEX7 Alleles
To determine whether PEX7 mutations have an effect
on the synthesis and/or stability of peroxin 7, we also
expressed the 10 different patient alleles in vitro, using
a coupled transcription-translation system (fig. 3). For
these studies, we used the same pcDNA3 constructs as
described above for expression in fibroblasts, because
pcDNA3 contains both a CMV promoter for expression
in mammalian cells and a T7 promoter for in vitro ex-
pression. As shown infigure 3, most patient alleles pro-
duced a protein of approximately the predicted size. In
the case of the 8-nt–duplication allele, however, no full-
length peroxin 7 could be detected, not even after long
exposures or when more lysate was layered.
Restoration of Luciferase Reading Frame by the 8-nt–
Duplication Allele
Because the 8-nt duplication occurs downstreamof two
potential in-frame translational start codons and because
no other in-frame AUG codons are present in PEX7
mRNA, we hypothesized that the duplication sequence
leads to restoration of the reading frame and the pro-
duction of functional peroxin 7. To further analyze this,
we studied the ability of the 8-nt–duplication containing
sequence to restore luciferase activity by fusing the cod-
ing sequence of luciferase in three different reading
frames behind a short 8-nt-duplication-containingPEX7
sequence followed by expression of these constructs in
COS cells (table 3). As translation initiation codon for
the 8-nt–duplication sequence in the fusion constructs,
the second ATG of PEX7 cDNA has been chosen, and
the first ATG of luciferase has been removed to prevent
internal initiation. The fusion constructs were transfected
into COS cells, and transfection efficiencywas determined
by cotransfection with a plasmid encoding b-galactosi-
dase. Luciferase activity was normalized by correcting
for b-galactosidase activity. As can be seen from table
3, luciferase activity was observed for both out-of-frame
fusions, although to varying degrees, with frame resto-
ration being slightly more efficient for the frame 2
fusion. As a control, a construct lacking both the PEX7-
derived sequence and the luciferase start codon showed
no luciferase activity, indicating that the observed lucif-
erase activity does not result from internal translational
initiation within the luciferase coding sequence. These
results indicate that molecular misreading must occur
during expression of these PEX7-luciferase fusion se-
quences, leading to partial correction of the introduced
frameshifts and resulting in low-level luciferase activity.
Discussion
We analyzed the PEX7 genotypes in a large cohort of
patients with clinical and biochemical diagnosis of
RCDP type 1. Initially, our genetic analysis involved se-
quence analysis of patient PEX7 cDNAs prepared from
total RNA isolated from primary skin fibroblasts or lym-
phocytes. After the recent elucidation of the PEX7 gene
structure (Braverman et al. 2000), we introduced a PCR-
based method for analysis of the PEX7 gene at the
genomic level, which involves sequencing of all coding
exons plus flanking intron-exon boundaries. In our pa-
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tients we found 22 different mutations, including 3 de-
letions, 1 insertion, and 9 missense, 6 nonsense, and
three splice-site mutations. In two patients, we could find
only one mutation in heterozygous form after analysis
of the PEX7 gene at the genomic level. SubsequentPEX7
cDNA analysis of these patients showed this mutation
in homozygous form, indicating that the second, un-
detected mutation affects mRNA expression and/or sta-
bility and, for example, might be located in the PEX7
promoter. Of the 22 mutations, only 4 had been reported
previously, as indicated in table 1. Of a fifth mutation,
IVS91GrC, only its consequence on mRNA splicing
has been reported (i.e., skipping of exon 9, comprising
nucleotides 804–903 [Purdue et al. 1997]). Themutation
underlying this aberrant splicing could be resolved only
by analysis of the PEX7 gene at the genomic level.
We found the nonsense mutation L292X to be by far
the most common mutation causing RCDP type 1, fol-
lowed by the A218V missense mutation. In our cohort,
the frequencies of the L292X and A218V mutations
were ∼52% and ∼12%, respectively, which is similar to
the frequencies of 49% and 6% that have been reported
by Braverman and colleagues (2000), who analyzed 36
patients with RCDP type 1 exclusively for three pre-
viously reported mutations, including these two. The
third mutation reported by Braverman and colleagues
(2000)—the G217R mutation, with a frequency of
7%—was observed in heterozygous form in only three
of our patients. The high frequency of the L292X mu-
tation has been shown to result from a founder effect
(Braverman et al. 2000).
Most of the mutations detected in our patients affect
amino acids conserved among peroxin 7 orthologues
from different phyla and/or amino acids that are pre-
dicted to have an important function in the confor-
mation of the protein. Peroxin 7 is a 323–amino acid
protein containing six WD repeats. Proteins with such
WD repeats have been implicated in diverse cellular pro-
cesses, and the WD repeats have been postulated to be
involved in establishing protein-protein interactions
(Smith et al. 1999). The crystal structures of two WD
repeat–containing proteins, the b-subunit of heterotri-
meric G proteins and Tup1 (Sondek et al. 1996; Sprague
et al. 2000), revealed that each WD repeat folds into
four b-strands (named “a,” “b,” “c,” and “d”), which
are arranged in an antiparallel fashion (fig. 4A). As a
result, the overall appearance of a WD-repeat protein
resembles that of a propeller, with as many blades as
the number ofWD repeats (Garcia-Higuera et al. 1998).
Secondary structure predictions revealed that peroxin 7
is composed solely of b-strands, indicating that it prob-
ably displays a propeller-like structure with seven
blades. On the basis of these predictions and of com-
parison with the crystallized WD repeat–containing
proteins, we created a folding topology diagram of per-
oxin 7 (fig. 4B). Interestingly, mapping the various mis-
sense mutations in the diagram revealed that, except for
the W95G mutation, they all affect amino acid residues
located in the exposed top surface of the propeller-like
structure, either in the connecting loops or at the ends
of the b-strands (fig. 4B). Since peroxin 7 has been
shown to interact with both the PTS2 sequence of
peroxisomal matrix proteins and the PTS1 receptor
peroxin 5 (Otera et al. 2000), this clustering suggests
that the mutations interfere with PTS2 and/or peroxin
5 binding. A similar clustering of mutations has been
reported elsewhere for the RAG2 gene in patients who
have severe combined immune deficiency syndrome
(Corneo et al. 2000), and the clustering has been dem-
onstrated to affect the interaction of RAG2 with RAG1
(Villa et al. 1998).
Using a PTS2-tagged GFP as reporter protein for
PTS2-mediated peroxisomal targeting, we were able to
distinguish between PEX7 alleles from patients with
severe disease and those from patients with mild disease:
whereas eight alleles identified in patients with severe
RCDP did not restore the PTS2-mediated targeting de-
fect in vitro, both alleles from patients with mild disease
did, although to varying degrees and only after CMV-
promoter–driven overexpression. In this respect, it
should be noted that previously we had been unable to
distinguish between fibroblasts from the patients with
mild disease and those with severe disease when we
analyzed these cells for the ability to import endogenous
peroxisomal thiolase and a PTS2-chloramphenicol acyl-
transferase reporter protein expressed from the RSV
promoter; none of the cells were able to import either
of these PTS2-containing proteins, although import of
a PTS1-containing reporter protein was normal (Motley
et al. 1996). The partial restoration upon overexpres-
sion of the H258R mutation, in conjunction with the
fact that this mutation is not located in the main cluster
of mutations in the topology model, suggests that the
histidine at position 258 is located in a region less im-
portant for protein-protein interaction. On the other
hand, in contrast to the other missense mutations, this
mutation involves the conserved substitution of an
amino acid, which may not completely abolish peroxin
7 activity.
The 8-nt–duplication allele found in two of the three
patients with mild disease is particularly interesting. As
the 8-nt duplication occurred just downstream of the
two potential start codons of PEX7 and no other AUG
codons are present in the PEX7 mRNA, we hypothe-
sized that the frameshift caused by the 8-nt dupli-
cation is corrected with a low frequency at either the
transcriptional or the translational level. Indeed, our
luciferase reading frame restoration assay confirmed the
occurrence of frame restoration within the duplication-
containing sequence. This result also makes a possible
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internal initiation event at non-AUG codons of PEX7,
as has been reported for other cellular mRNAs, unlikely
(Ronsin et al. 1999; Arnaud et al. 1999). At this mo-
ment, it is not clear whether the frame restoration of
the 8-nt duplication PEX7 allele results from molecular
misreading at the transcriptional level, the translational
level, or both. Unfortunately, this could not be resolved
using an in vitro coupled transcription-translation sys-
tem, because, in this system, no detectable peroxin 7
protein was synthesized. A possible explanation for this
could be that frame restoration at the transcriptional
level may be mediated only by RNA polymerase II but
not by the phage T7 polymerase used in the in vitro
system. Alternatively, the frame restoration could result
from ribosomal shifting, which may occur only in intact
cells but not in reticulocyte lysates.
The repeat-containing sequence in PEX7 that under-
goes frame restoration does not resemble any previously
described sequence involved in transcriptional (van
Leeuwen et al. 1998; Linton et al. 1997; van den Hurk
et al. 2001) or translational (Giedroc et al. 2000) mis-
reading. Indeed, searching of the sequence databases
indicates that this repeat-containing sequence is unique
to PEX7. To our knowledge, this is only the third ex-
ample of a frame restoration event resulting in amelio-
ration of a predicted severe phenotype reported to date.
The other two examples involve frame restoration due
to transcriptional and/or translational errors occurring
in a stretch of 10 adenines created by the deletion of a
thymidine in the factor VIII gene, resulting in unex-
pectedly mild hemophilia A (Young et al. 1997), and
the insertion of an additional adenine into a stretch of
eight adenines created by the deletion of a cytosine in
the apolipoprotein B gene, resulting in hypobetalipo-
proteinemia (Linton et al. 1992).
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